Journal article icon

Journal article

Cross-reactive bactericidal antimeningococcal antibodies can be isolated from convalescing invasive meningococcal disease patients using reverse vaccinology 2.0

Abstract:

The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and its huge potential for the generation of further diversity. Thus, the continuous search for candidate antigens that will compose supplementary or replacement vaccines is mandated. Here, we describe...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Medical Sciences Office
Department:
Oxford, MSD, Medical Sciences Division
Role:
Author
More by this author
Institution:
University of Oxford
Oxford college:
Balliol College
Role:
Author
More from this funder
Name:
MeningitisNow
Funding agency for:
Screaton, G
Kroll, J
Publisher:
Frontiers Research Foundation
Journal:
Frontiers in Immunology More from this journal
Volume:
9
Publication date:
2018-07-16
Acceptance date:
2018-06-29
DOI:
EISSN:
1664-3224
Keywords:
Pubs id:
pubs:891921
UUID:
uuid:6a75e58a-c0db-46c8-8704-f6a0c2aa4e08
Local pid:
pubs:891921
Source identifiers:
891921
Deposit date:
2018-08-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP